3rd Generation Tankless Inhaled Nitric Oxide System Gets FDA Approval
The US FDA has approved the third Generation Genosyl Delivery System, a tankless inhaled nitric oxide (iNO) therapy device, according to manufacturer Vero Biotech Inc.
The US FDA has approved the third Generation Genosyl Delivery System, a tankless inhaled nitric oxide (iNO) therapy device, according to manufacturer Vero Biotech Inc.
Beyond Air Inc will initiate a clinical study of its LungFit tankless nitric oxide (NO) system for evaluation of the safety and efficacy of high concentration inhaled NO given intermittently to adults hospitalized with acute viral pneumonia, including SARS-CoV-2.
This clinical trial will monitor patients with mild to moderate cases of COVID-19 to see how they respond to inhaled nitric oxide as a treatment.
Preterm infants born younger than 29 weeks’ gestational age who were treated for pulmonary...
Read MoreA new compound developed by researchers from Spain allows for the detection of nitric oxide by fluorescence.
Read MoreLow levels of both oxygen and nitric oxide appear to have an unfortunate synergy for patients with sickle cell disease, researchers report.
Read More